{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009691","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.779352+00:00","generated_at":"2026-06-04T06:46:16.817704+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perspective Therapeutics FY2023 net loss $46.5M; raised $177.2M in Q1 2024 financings","bullets":["Net loss $46.5M ($0.17/share) vs $10.8M ($0.08) in FY2022; R&D expenses surged to $21.3M from $0.9M.","Cash $9.2M at Dec 31, 2023; subsequent private placements & public offering raised ~$177.2M gross in Q1 2024.","Phase 1/2a trials for [212Pb]VMT-α-NET (NETs) and [212Pb]VMT01 (melanoma) advanced; Cohort 2 enrolling.","Entered collaboration with Bristol Myers Squibb for VMT01+nivolumab combo; Lantheus gets option for VMT-α-NET license.","Acquired radiopharmaceutical manufacturing facility in Somerset, NJ; sold brachytherapy business to GT Medical."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009691","json":"https://secwatch.observer/filing/0001437749-24-009691.json","markdown":"https://secwatch.observer/filing/0001437749-24-009691.md","text":"https://secwatch.observer/filing/0001437749-24-009691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/0001437749-24-009691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/isr20240327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:46:16.817704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"104e38c587b84c75f4918079c73b3057ad0f8746","claim":"Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774924009691/0001437749-24-009691-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}